{"schema":"hottub-news/list/v1","item_schema":"hottub-news/item/v1","count":4,"sponsored":0,"items":[{"id":"n_vm462doedwsw5baludka","seq":1348132,"kind":"press_release","title":"Candel Therapeutics to Present at the SITC 2026 Annual Meeting","url":"https://www.globenewswire.com/news-release/2026/10/02/3373820/0/en/candel-therapeutics-to-present-at-the-sitc-2026-annual-meeting.html","summary":"NEEDHAM, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that the Company will present data from its aglatimagene besadenovec program in non-small cell lung cancer (NSCLC) in patients with progressive NSCLC despite immune checkpoint inhibitor (ICI)…","published":"2026-10-02T13:00:00Z","seen":"2026-10-02T13:07:57Z","lang":"en","source":{"id":"globenewswire-public","name":"GlobeNewswire — public companies","domain":"globenewswire.com","outlet":{"wikidata":"Q5570956","name":"GlobeNewswire","type":"other","country":"US","designations":["business","press release distributor"]}},"via":"globenewswire-public","topics":["business","nasdaq:cadl","us1374041093"],"entities":[{"id":"Q30283508","name":"Candel Therapeutics","type":"org"},{"id":"Q16900986","name":"Swinomish Indian Tribal Community","type":"event"}],"mentions":2,"story":"st_vm462doedwsw5baludka","category":"economy-business","category_p":0.31,"category2":"health","sentiment":"neutral","tone":0.37,"political":0.08},{"id":"n_vnabvqt7zqocmvkrlxnq","seq":1209860,"kind":"press_release","title":"Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://www.globenewswire.com/news-release/2026/10/01/3373373/0/en/candel-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html","summary":"NEEDHAM, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that on September 30, 2026, the Compensation Committee of Candel’s Board of Directors (the Board) granted to 4 new employees, stock options to purchase an aggregate of 85,900 shares of the Company’s…","published":"2026-10-01T20:05:00Z","seen":"2026-10-01T20:16:11Z","lang":"en","source":{"id":"globenewswire-public","name":"GlobeNewswire — public companies","domain":"globenewswire.com","outlet":{"wikidata":"Q5570956","name":"GlobeNewswire","type":"other","country":"US","designations":["business","press release distributor"]}},"via":"globenewswire-public","topics":["business","nasdaq:cadl","us1374041093"],"entities":[{"id":"Q30283508","name":"Candel Therapeutics","type":"org"}],"story":"st_b4wvtkclozu3hzn3nmqq","category":"economy-business","category_p":0.64,"sentiment":"neutral","tone":0.2,"political":0.09},{"id":"n_rzwgj7c25bv5ba5wrqqq","seq":901290,"kind":"press_release","title":"Candel Therapeutics Announces Integrated Clinical and Biomarker Data That Showed Durable Local and Systemic Immune Activation after Aglatimagene Besadenovec in Intermediate-Risk Localized Prostate Cancer","url":"https://www.globenewswire.com/news-release/2026/09/30/3371862/0/en/candel-therapeutics-announces-integrated-clinical-and-biomarker-data-that-showed-durable-local-and-systemic-immune-activation-after-aglatimagene-besadenovec-in-intermediate-risk-lo.html","summary":"NEEDHAM, Mass., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced novel immunological biomarker data from the ongoing phase 2 PrTK05 trial ( NCT07332000 ) in patients with intermediate-risk localized prostate cancer. These data, together with histologic and clinical…","published":"2026-09-30T12:30:00Z","seen":"2026-09-30T12:37:48Z","lang":"en","source":{"id":"globenewswire-public","name":"GlobeNewswire — public companies","domain":"globenewswire.com","outlet":{"wikidata":"Q5570956","name":"GlobeNewswire","type":"other","country":"US","designations":["business","press release distributor"]}},"via":"globenewswire-public","topics":["business","nasdaq:cadl","us1374041093"],"entities":[{"id":"Q30283508","name":"Candel Therapeutics","type":"org"},{"id":"Q181257","name":"prostate cancer","type":"other"}],"story":"st_zzezcrelyqsr2h4u4atq","category":"health","category_p":0.64,"sentiment":"neutral","tone":0.15,"political":0.05},{"id":"n_zzezcrelyqsr2h4u4atq","seq":897533,"kind":"press_release","title":"Candel Therapeutics Announces New Data Showing Sustained Immune Remodeling More Than Two Years After Aglatimagene Besadenovec Treatment in Localized Prostate Cancer at ASTRO 2026","url":"https://www.globenewswire.com/news-release/2026/09/30/3371847/0/en/candel-therapeutics-announces-new-data-showing-sustained-immune-remodeling-more-than-two-years-after-aglatimagene-besadenovec-treatment-in-localized-prostate-cancer-at-astro-2026.html","summary":"NEEDHAM, Mass., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced the presentation of new biomarker data from its completed phase 3 clinical trial of aglatimagene besadenovec (aglatimagene) in patients with localized intermediate- to high-risk prostate cancer at the…","published":"2026-09-30T12:05:00Z","seen":"2026-09-30T12:13:15Z","lang":"en","source":{"id":"globenewswire-all","name":"GlobeNewswire — all","domain":"globenewswire.com","outlet":{"wikidata":"Q5570956","name":"GlobeNewswire","type":"other","country":"US","designations":["business","press release distributor"]}},"via":"globenewswire-all","topics":["business","nasdaq:cadl","us1374041093"],"entities":[{"id":"Q30283508","name":"Candel Therapeutics","type":"org"}],"mentions":2,"story":"st_zzezcrelyqsr2h4u4atq","category":"health","category_p":0.6,"sentiment":"positive","tone":0.3,"political":0.04}]}